Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Dec 02, 2022 2:23pm
143 Views
Post# 35147213

RE:RE:RE:RE:“Designated news release””

RE:RE:RE:RE:“Designated news release””I would've preferred a conference call today laying out why they think the new approach is best, what they've seen in the trials to support that, and discussion around what next steps look like and the challenges from the old trial design. The details of budgets, new business plan, etc can come later. Maybe it wouldn't have helped much today, but they cannot wait and leave the markets open to their own interpretations like they have before.

Wino115 wrote: Given most of the analysts wrote up notes it seems they are doing the fairly traditional approach of using those as the loud speaker on what they are saying, so in essence that is their "call" and how they are disseminating and discussing it via those analysts and what may seep in to the news.  So what those analysts are saying is what they heard and their interpretation.

If I'm not wrong, I think they come out with a sort of year end update prior to actual full quarterly release so that is probably where they will talk in more depth and disclose the busines plan for the year in generalities (no doubt the objective to ramp revenues best they can and cut costs as they can do that now with little effect).  Those should be taken as a positive strategy from here, and maybe they can keep up the decent sales growth seen over the last 2 years, which is what's needed to stabilize and get the price back up.  So you probably won't see one this week, but once they've implemented the plan, approved budgets, etc... they likely will get back in front of the market.  

PWIB123 wrote: Wino, is there any reason why they could'nt have had that conference call this morning?  Waiting 4-6 weeks to provide more clarity to the market is not an option in my opinion.
 




<< Previous
Bullboard Posts
Next >>